title: Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference.
abstract: Vehicle formulation plays a major role in patient adherence to topical psoriasis treatments. The objective of this study was to conduct a preliminary assessment of patient preference for ointment versus topical suspension formulations of calcipotriene 0.005%-betamethasone dipropionate 0.064% for treatment of plaque psoriasis. In our small cohort of 20 participants with mild to moderate plaque psoriasis, the topical suspension formulation was preferred over the ointment, though the difference was not statistically significant (P=.32). Overall, the topical suspension was rated as moderately appealing, while the ointment was rated as slightly appealing (P=.06). Subgroup analyses were limited due to the small sample size. The results of this study may provide clinicians with an alternative topical treatment of plaque psoriasis that provides the benefits of a combination product. In clinical practice, it may be best to offer patients both formulations and they can choose the product that is right for them.
authors.affiliation: Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071, USA. lsandovaldo@gmail.com.
authors.forename: Laura F
authors.initials: LF
authors.lastname: Sandoval
authors.forename: Karen E
authors.initials: KE
authors.lastname: Huang
authors.forename: Jessica
authors.initials: J
authors.lastname: Harrison
authors.forename: Adele
authors.initials: A
authors.lastname: Clark
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D057240:Patient Preference; D010865:Pilot Projects; D011565:Psoriasis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D012720:Severity of Illness Index; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D009824:Ointments; D013535:Suspensions; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol